Navigation Links
CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
Date:10/28/2008

INDIANAPOLIS, Oct. 28 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced today that it has appointed Linda Hogan as Vice President of Business Development. In this position, Hogan will apply more than 25 years of experience in the pharmaceutical and biopharmaceutical industries to drive CoLucid's business development strategies. She will lead partnering initiatives and transactions for the company's rapidly advancing pipeline of compounds for the treatment of central nervous system (CNS) disorders.

Hogan continues to serve as an Executive in Residence at Care Capital, LLC where she assists with the sourcing and evaluation of potential investment opportunities, including the formation of new companies, and provides business development support to portfolio companies. She previously served as Vice President of Business Development with Clearview Projects, Inc. and was Vice President of Business Development at Aventis. Hogan received an MBA from Rockhurst College and an MS in Hospital Pharmacy at the University of Kansas School of Pharmacy.

The company also announced that Nadia Rupniak has been promoted to Vice President of Research and Development, where she will lead the advancement of the company's late-stage and preclinical therapeutic candidates.

Rupniak has more than 20 years of experience in the pharmaceutical industry, including more than two years with CoLucid. She previously held positions at Merck and at Dynogen Pharmaceuticals, Inc, where she served as the head of technology transfer.

"We are building and adding to our team to support the continued advancement of COL-144 for the acute treatment of migraine and our other drug candidates," said James White, CEO of CoLucid Pharmaceuticals. "We congratulate Nadia Rupniak on her promotion, which reflects the important contributions she has made in helping CoLucid meet our clinical and research objectives, and we are very pleased to bring Linda Hogan on board. Linda is a skilled and accomplished business development professional who is able to draw on a breadth of experience at Care Capital and Clearview to help advance CoLucid's partnering initiatives."

"I look forward to working with CoLucid to help identify key business targets and to set the future direction of CoLucid's product development and partnering strategies," said Hogan. "I am very excited about the market and partnering potential for the company's pipeline of innovative CNS product candidates."

CoLucid Pharmaceuticals recently announced positive results from its Phase II clinical study of its lead compound, COL-144, in the treatment of acute migraine. Findings from the study demonstrated that COL-144 is effective in relieving migraine headaches and is well tolerated.

COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapy. COL-144 selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway. In addition to COL-144, CoLucid's pipeline includes a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. COL-204, the lead compound in the conjugated stigmine program, is expected to enter clinical development in 2009 for wake promotion.

About CoLucid Pharmaceuticals, Inc.

CoLucid Pharmaceuticals was founded in December 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment for central nervous system (CNS) disorders. The company's pipeline includes COL-144, a novel treatment for migraine headache, and a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. For more information, please visit CoLucid at http://www.colucid.com.


'/>"/>
SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound
2. Anadys Pharmaceuticals to Present at Bio Investor Forum
3. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
4. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
5. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
6. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
7. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
8. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
9. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
10. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
11. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Regular gym ... find themselves having to wait longer to access the treadmills. It’s a predictable trend. ... resolutions to lose weight and get in shape by joining gyms, starting new walking ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a ... individuals in the event they are experiencing an illness. Migraines are a severe form ... are afflicted with migraines would not wish the pain on their worst enemy, the ...
(Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
(Date:2/4/2016)... ... February 04, 2016 , ... American Addiction Centers ... the start of Project HoldSpace. Through the partnership, the two organizations seek to ... youth between the ages of 13 and 18. Currently focused on Ohio schools, ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Patients in Alabama seeking ... therapy no longer have to travel out of state. ... Urology Centers of Alabama to provide a total ... qualifying patients. Alabama is ... of prostate cancer using many different modalities. They are the ...
(Date:2/5/2016)... 2016 --> ... that the global active pharmaceuticals ingredients (APIs) market stood ... reach US$185.9 bn by 2020. It is expected to ... 2020. The title of the report is "Active Pharmaceutical ... and by Therapeutic Area) - Global Industry Analysis, Size, ...
(Date:2/5/2016)... 2016 Site Profile: --> ... - The Speech Recognition People, announced their latest primary healthcare case ... care, reduce turnaround times and to save the practice money. ... since 2013 Challenge: --> ,- Wirral CCG ... - Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology: